The programme supports independent clinical and observational research, which aligns with Eniola's experience as a pharmacist and researcher. The focus on elranatamab in relapsed or refractory multiple myeloma may not be directly related to Eniola's work on the Conjunctive Consolidation Threshold (CCT) model, but the grant's support for independent research makes it a potential fit. Eniola's strong background in pharmacology and research experience make them a competitive candidate for this grant.